Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amarin Corporation PLC stock logo
AMRN
Amarin
$15.16
+4.4%
$14.46
$7.08
$17.49
$300.67M0.8481,295 shs88,516 shs
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$10.49
+13.5%
$8.35
$5.20
$10.67
$1.25B1.231.95 million shs7.74 million shs
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
$40.00
$40.00
$15.25
$43.00
$1.19B1.7710,339 shsN/A
CureVac N.V. stock logo
CVAC
CureVac
$5.41
+0.4%
$5.17
$2.37
$5.72
$1.21B2.53838,251 shs516,327 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amarin Corporation PLC stock logo
AMRN
Amarin
+4.41%-1.49%-8.95%+38.96%+11.14%
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
+13.53%+17.47%+40.05%+27.77%+78.40%
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
0.00%0.00%0.00%0.00%+4.03%
CureVac N.V. stock logo
CVAC
CureVac
+0.37%-0.92%+0.19%+51.97%+43.50%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amarin Corporation PLC stock logo
AMRN
Amarin
0.5783 of 5 stars
0.55.00.00.01.70.00.6
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
2.3275 of 5 stars
2.51.00.00.02.00.83.1
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
N/AN/AN/AN/AN/AN/AN/AN/A
CureVac N.V. stock logo
CVAC
CureVac
4.4413 of 5 stars
4.13.00.04.92.70.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amarin Corporation PLC stock logo
AMRN
Amarin
1.00
Sell$12.00-20.84% Downside
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
3.00
Buy$12.0014.39% Upside
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
0.00
N/AN/AN/A
CureVac N.V. stock logo
CVAC
CureVac
2.20
Hold$6.8326.31% Upside

Current Analyst Ratings Breakdown

Latest AMRN, CVAC, AUPH, and CALT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/1/2025
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$8.00 ➝ $9.00
7/30/2025
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$17.00
6/26/2025
CureVac N.V. stock logo
CVAC
CureVac
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Neutral$12.00 ➝ $5.50
6/25/2025
Amarin Corporation PLC stock logo
AMRN
Amarin
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSell ➝ Sell$7.00 ➝ $12.00
6/13/2025
CureVac N.V. stock logo
CVAC
CureVac
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$7.00 ➝ $5.00
6/12/2025
CureVac N.V. stock logo
CVAC
CureVac
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeMarket Perform
6/12/2025
CureVac N.V. stock logo
CVAC
CureVac
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/28/2025
CureVac N.V. stock logo
CVAC
CureVac
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$10.00
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amarin Corporation PLC stock logo
AMRN
Amarin
$228.61M1.37N/AN/A$22.45 per share0.68
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$235.13M6.03$0.35 per share29.98$2.68 per share3.91
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
$1.60B0.74N/AN/A$1.06 per share37.74
CureVac N.V. stock logo
CVAC
CureVac
$579.18M2.10$0.88 per share6.17$3.36 per share1.61
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amarin Corporation PLC stock logo
AMRN
Amarin
-$82.18M-$3.67N/AN/AN/A-47.22%-21.18%-15.00%N/A
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$5.75M$0.2824.4018.73N/A23.31%19.57%13.60%N/A
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/A
CureVac N.V. stock logo
CVAC
CureVac
$175.50M$0.925.88N/AN/A35.44%30.89%25.54%8/13/2025 (Estimated)

Latest AMRN, CVAC, AUPH, and CALT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
CureVac N.V. stock logo
CVAC
CureVac
-$0.15N/AN/AN/A$4.27 millionN/A
7/31/2025Q2 2025
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$0.17$0.16-$0.01$0.16$64.27 million$70.01 million
7/30/2025Q2 2025
Amarin Corporation PLC stock logo
AMRN
Amarin
-$0.66-$0.03+$0.63-$0.03$45.45 million$72.74 million
5/22/2025Q1 2025
CureVac N.V. stock logo
CVAC
CureVac
-$0.16-$0.24-$0.08-$0.24$4.27 million$0.94 million
5/12/2025Q1 2025
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$0.08$0.16+$0.08$0.16$61.06 million$62.47 million
5/7/2025Q1 2025
Amarin Corporation PLC stock logo
AMRN
Amarin
-$0.06-$0.04+$0.02-$0.04$50.75 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amarin Corporation PLC stock logo
AMRN
Amarin
N/AN/AN/AN/AN/A
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
N/AN/AN/AN/AN/A
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
N/AN/AN/AN/AN/A
CureVac N.V. stock logo
CVAC
CureVac
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amarin Corporation PLC stock logo
AMRN
Amarin
N/A
3.26
2.55
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
0.16
5.93
5.26
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
9.44
2.69
2.59
CureVac N.V. stock logo
CVAC
CureVac
0.05
7.65
7.64

Institutional Ownership

CompanyInstitutional Ownership
Amarin Corporation PLC stock logo
AMRN
Amarin
22.25%
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
36.83%
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
2.83%
CureVac N.V. stock logo
CVAC
CureVac
17.26%

Insider Ownership

CompanyInsider Ownership
Amarin Corporation PLC stock logo
AMRN
Amarin
3.30%
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
12.20%
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
2.20%
CureVac N.V. stock logo
CVAC
CureVac
2.15%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amarin Corporation PLC stock logo
AMRN
Amarin
36020.71 million20.02 millionOptionable
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
300135.10 million118.62 millionOptionable
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
18029.79 million29.14 millionOptionable
CureVac N.V. stock logo
CVAC
CureVac
880224.34 million219.52 millionOptionable

Recent News About These Companies

UBS Downgrades CureVac N.V. (CVAC)
CureVac Announces Voting Results of General Meeting
CureVac Stock Soars on BioNTech Buyout
BioNTech boosts cancer mRNA pipeline with CureVac acquisition

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amarin stock logo

Amarin NASDAQ:AMRN

$15.16 +0.64 (+4.41%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$15.08 -0.09 (-0.56%)
As of 08/1/2025 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Aurinia Pharmaceuticals stock logo

Aurinia Pharmaceuticals NASDAQ:AUPH

$10.49 +1.25 (+13.53%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$10.42 -0.08 (-0.71%)
As of 08/1/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Calliditas Therapeutics AB (publ) stock logo

Calliditas Therapeutics AB (publ) NASDAQ:CALT

$40.00 0.00 (0.00%)
As of 08/1/2025

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

CureVac stock logo

CureVac NASDAQ:CVAC

$5.41 +0.02 (+0.37%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$5.40 -0.02 (-0.28%)
As of 08/1/2025 06:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.